Abstract
In recent years, small non-coding RNAs (ncRNAs) have emerged as a new player in the realm of cancer therapeutics. Their unique capacity to directly modulate genetic networks and target oncogenes positions them as valuable complements to existing small-molecule drugs. Concurrently, the advancement of small ncRNA-based therapeutics has rekindled the pursuit of efficacious in vivo delivery strategies. In this review, we provide an overview of the most current clinical and preclinical studies in the field of small ncRNA-based cancer therapeutics. Furthermore, we shed light on the pivotal challenges hindering the successful translation of these promising therapies into clinical practice, with a specific focus on delivery methods, aiming to stimulate innovative approaches to address this foundational aspect of cancer treatment.
| Original language | English |
|---|---|
| Article number | 1297413 |
| Journal | Frontiers in Molecular Biosciences |
| Volume | 10 |
| DOIs | |
| State | Published - 2023 |
Bibliographical note
Publisher Copyright:Copyright © 2024 Yang, Liang and Tong.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by NIH/NIBIB (R01EB026893 to ST) and NIH/NHLBI (R21HL166178 to ST).
| Funders | Funder number |
|---|---|
| National Institutes of Health (NIH) | |
| National Heart, Lung, and Blood Institute (NHLBI) | R21HL166178 |
| National Institute of Biomedical Imaging and Bioengineering | R01EB026893 |
Keywords
- cancer
- in vivo delivery
- miRNA
- siRNA
- small non-coding RNA
ASJC Scopus subject areas
- Biochemistry
- Molecular Biology
- Biochemistry, Genetics and Molecular Biology (miscellaneous)
